Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Founder effect in the Horn of Africa for an insulin receptor mutation that may impair receptor recycling.

Raffan E, Soos MA, Rocha N, Tuthill A, Thomsen AR, Hyden CS, Gregory JW, Hindmarsh P, Dattani M, Cochran E, Al Kaabi J, Gorden P, Barroso I, Morling N, O'Rahilly S, Semple RK.

Diabetologia. 2011 May;54(5):1057-65. doi: 10.1007/s00125-011-2066-z. Epub 2011 Feb 12.

2.

Treatment of type B insulin resistance: a novel approach to reduce insulin receptor autoantibodies.

Malek R, Chong AY, Lupsa BC, Lungu AO, Cochran EK, Soos MA, Semple RK, Balow JE, Gorden P.

J Clin Endocrinol Metab. 2010 Aug;95(8):3641-7. doi: 10.1210/jc.2010-0167. Epub 2010 May 19.

3.

A truncation mutation in TBC1D4 in a family with acanthosis nigricans and postprandial hyperinsulinemia.

Dash S, Sano H, Rochford JJ, Semple RK, Yeo G, Hyden CS, Soos MA, Clark J, Rodin A, Langenberg C, Druet C, Fawcett KA, Tung YC, Wareham NJ, Barroso I, Lienhard GE, O'Rahilly S, Savage DB.

Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9350-5. doi: 10.1073/pnas.0900909106. Epub 2009 May 22.

4.

Autoimmune forms of hypoglycemia.

Lupsa BC, Chong AY, Cochran EK, Soos MA, Semple RK, Gorden P.

Medicine (Baltimore). 2009 May;88(3):141-53. doi: 10.1097/MD.0b013e3181a5b42e. Review.

5.

IRS2 variants and syndromes of severe insulin resistance.

Bottomley WE, Soos MA, Adams C, Guran T, Howlett TA, Mackie A, Miell J, Monson JP, Temple R, Tenenbaum-Rakover Y, Tymms J, Savage DB, Semple RK, O'Rahilly S, Barroso I.

Diabetologia. 2009 Jun;52(6):1208-11. doi: 10.1007/s00125-009-1345-4. Epub 2009 Apr 18. No abstract available.

6.

Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis.

Semple RK, Sleigh A, Murgatroyd PR, Adams CA, Bluck L, Jackson S, Vottero A, Kanabar D, Charlton-Menys V, Durrington P, Soos MA, Carpenter TA, Lomas DJ, Cochran EK, Gorden P, O'Rahilly S, Savage DB.

J Clin Invest. 2009 Feb;119(2):315-22. doi: 10.1172/JCI37432. Epub 2009 Jan 26.

7.

Severe insulin resistance due to anti-insulin antibodies: response to plasma exchange and immunosuppressive therapy.

Greenfield JR, Tuthill A, Soos MA, Semple RK, Halsall DJ, Chaudhry A, O'Rahilly S.

Diabet Med. 2009 Jan;26(1):79-82. doi: 10.1111/j.1464-5491.2008.02621.x.

PMID:
19125765
8.

Plasma adiponectin as a marker of insulin receptor dysfunction: clinical utility in severe insulin resistance.

Semple RK, Cochran EK, Soos MA, Burling KA, Savage DB, Gorden P, O'Rahilly S.

Diabetes Care. 2008 May;31(5):977-9. doi: 10.2337/dc07-2194. Epub 2008 Feb 25.

PMID:
18299442
9.

Analysis of genetic variation in Akt2/PKB-beta in severe insulin resistance, lipodystrophy, type 2 diabetes, and related metabolic phenotypes.

Tan K, Kimber WA, Luan J, Soos MA, Semple RK, Wareham NJ, O'Rahilly S, Barroso I.

Diabetes. 2007 Mar;56(3):714-9.

10.

Paradoxical elevation of high-molecular weight adiponectin in acquired extreme insulin resistance due to insulin receptor antibodies.

Semple RK, Halberg NH, Burling K, Soos MA, Schraw T, Luan J, Cochran EK, Dunger DB, Wareham NJ, Scherer PE, Gorden P, O'Rahilly S.

Diabetes. 2007 Jun;56(6):1712-7. Epub 2007 Feb 26.

11.

Functional characterization of a novel insulin receptor mutation contributing to Rabson-Mendenhall syndrome.

Tuthill A, Semple RK, Day R, Soos MA, Sweeney E, Seymour PJ, Didi M, O'rahilly S.

Clin Endocrinol (Oxf). 2007 Jan;66(1):21-6.

PMID:
17201797
12.

Elevated plasma adiponectin in humans with genetically defective insulin receptors.

Semple RK, Soos MA, Luan J, Mitchell CS, Wilson JC, Gurnell M, Cochran EK, Gorden P, Chatterjee VK, Wareham NJ, O'Rahilly S.

J Clin Endocrinol Metab. 2006 Aug;91(8):3219-23. Epub 2006 May 16.

PMID:
16705075
13.

Muscle glycogen inharmoniously regulates glycogen synthase activity, glucose uptake, and proximal insulin signaling.

Jensen J, Jebens E, Brennesvik EO, Ruzzin J, Soos MA, Engebretsen EM, O'Rahilly S, Whitehead JP.

Am J Physiol Endocrinol Metab. 2006 Jan;290(1):E154-E162. Epub 2005 Aug 23.

14.

Successful treatment of Type B insulin resistance in a patient with otherwise quiescent systemic lupus erythematosus.

Coll AP, Morganstein D, Jayne D, Soos MA, O'Rahilly S, Burke J.

Diabet Med. 2005 Jun;22(6):814-5. No abstract available.

PMID:
15910639
15.

Familial partial lipodystrophy associated with compound heterozygosity for novel mutations in the LMNA gene.

Savage DB, Soos MA, Powlson A, O'Rahilly S, McFarlane I, Halsall DJ, Barroso I, Thomas EL, Bell JD, Scobie I, Belchetz PE, Kelly WF, Schafer AJ.

Diabetologia. 2004 Apr;47(4):753-6. No abstract available.

PMID:
15298354
16.

A family with severe insulin resistance and diabetes due to a mutation in AKT2.

George S, Rochford JJ, Wolfrum C, Gray SL, Schinner S, Wilson JC, Soos MA, Murgatroyd PR, Williams RM, Acerini CL, Dunger DB, Barford D, Umpleby AM, Wareham NJ, Davies HA, Schafer AJ, Stoffel M, O'Rahilly S, Barroso I.

Science. 2004 May 28;304(5675):1325-8.

17.

Genetic variants in human sterol regulatory element binding protein-1c in syndromes of severe insulin resistance and type 2 diabetes.

Laudes M, Barroso I, Luan J, Soos MA, Yeo G, Meirhaeghe A, Logie L, Vidal-Puig A, Schafer AJ, Wareham NJ, O'Rahilly S.

Diabetes. 2004 Mar;53(3):842-6.

18.

Hypoketotic hypofattyacidaemic hypoinsulinaemic hypoglycaemia in a child with hemihypertrophy? A new syndrome.

Hussain K, Bodamer OA, Cameron FJ, Camacho-Hubner C, Soos MA, Jones J, Krywawych S, O'Rahilly S, Aynsley-Green A.

Horm Res. 2004;61(5):222-7. Epub 2004 Feb 2.

PMID:
14764948
19.

Deletion of V335 from the L2 domain of the insulin receptor results in a conformationally abnormal receptor that is unable to bind insulin and causes Donohue's syndrome in a human subject.

George S, Johansen A, Soos MA, Mortensen H, Gammeltoft S, Saudek V, Siddle K, Hansen L, O'Rahilly S.

Endocrinology. 2003 Feb;144(2):631-7.

PMID:
12538626
20.

Digenic inheritance of severe insulin resistance in a human pedigree.

Savage DB, Agostini M, Barroso I, Gurnell M, Luan J, Meirhaeghe A, Harding AH, Ihrke G, Rajanayagam O, Soos MA, George S, Berger D, Thomas EL, Bell JD, Meeran K, Ross RJ, Vidal-Puig A, Wareham NJ, O'Rahilly S, Chatterjee VK, Schafer AJ.

Nat Genet. 2002 Aug;31(4):379-84. Epub 2002 Jul 15. Erratum in: Nat Genet 2002 Sep;32(1):211.

PMID:
12118251
21.

Role of insulin receptor dimerization domains in ligand binding, cooperativity, and modulation by anti-receptor antibodies.

Surinya KH, Molina L, Soos MA, Brandt J, Kristensen C, Siddle K.

J Biol Chem. 2002 May 10;277(19):16718-25. Epub 2002 Mar 1.

22.

Class II phosphoinositide 3-kinase is activated by insulin but not by contraction in skeletal muscle.

Soos MA, Jensen J, Brown RA, O'Rahilly S, Shepherd PR, Whitehead JP.

Arch Biochem Biophys. 2001 Dec 15;396(2):244-8.

PMID:
11747303
23.

Specificity in ligand binding and intracellular signalling by insulin and insulin-like growth factor receptors.

Siddle K, Ursø B, Niesler CA, Cope DL, Molina L, Surinya KH, Soos MA.

Biochem Soc Trans. 2001 Aug;29(Pt 4):513-25. Review.

PMID:
11498020
24.

Hypoglycemia and resistance to ketoacidosis in a subject without functional insulin receptors.

Ogilvy-Stuart AL, Soos MA, Hands SJ, Anthony MY, Dunger DB, O'Rahilly S.

J Clin Endocrinol Metab. 2001 Jul;86(7):3319-26.

PMID:
11443207
25.

Defect in insulin-like growth factor-1 survival mechanism in atherosclerotic plaque-derived vascular smooth muscle cells is mediated by reduced surface binding and signaling.

Patel VA, Zhang QJ, Siddle K, Soos MA, Goddard M, Weissberg PL, Bennett MR.

Circ Res. 2001 May 11;88(9):895-902.

PMID:
11348998
27.

Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension.

Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TD, Lewis H, Schafer AJ, Chatterjee VK, O'Rahilly S.

Nature. 1999 Dec 23-30;402(6764):880-3.

PMID:
10622252
28.

Multiple molecular mechanisms of insulin receptor dysfunction in a patient with Donohue syndrome.

Whitehead JP, Soos MA, Jackson R, Tasic V, Kocova M, O'Rahilly S.

Diabetes. 1998 Aug;47(8):1362-4. No abstract available.

PMID:
9703342
29.
31.

Congenital leptin deficiency is associated with severe early-onset obesity in humans.

Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, Sewter CP, Digby JE, Mohammed SN, Hurst JA, Cheetham CH, Earley AR, Barnett AH, Prins JB, O'Rahilly S.

Nature. 1997 Jun 26;387(6636):903-8.

PMID:
9202122
32.

Insulin-like growth factor (IGF)-I A- and B-domain analogues with altered type 1 IGF and insulin receptor binding specificities.

Shooter GK, Magee B, Soos MA, Francis GL, Siddle K, Wallace JC.

J Mol Endocrinol. 1996 Dec;17(3):237-46.

PMID:
8981230
33.

Functional activation of mutant human insulin receptor by monoclonal antibody.

Krook A, Soos MA, Kumar S, Siddle K, O'Rahilly S.

Lancet. 1996 Jun 8;347(9015):1586-90.

PMID:
8667867
34.

Inhibitors of phosphoinositide 3-kinase block exocytosis but not endocytosis of transferrin receptors in 3T3-L1 adipocytes.

Shepherd PR, Soos MA, Siddle K.

Biochem Biophys Res Commun. 1995 Jun 15;211(2):535-9.

PMID:
7794266
35.

Hybrid and atypical insulin/insulin-like growth factor I receptors.

Siddle K, Soos MA, Field CE, Navé BT.

Horm Res. 1994;41 Suppl 2:56-64; discussion 65. Review.

PMID:
8088705
38.

Signaling-competent receptor chimeras allow mapping of major insulin receptor binding domain determinants.

Schumacher R, Soos MA, Schlessinger J, Brandenburg D, Siddle K, Ullrich A.

J Biol Chem. 1993 Jan 15;268(2):1087-94.

39.

Immunological studies of type I IGF receptors and insulin receptors: characterisation of hybrid and atypical receptor subtypes.

Soos MA, Navé BT, Siddle K.

Adv Exp Med Biol. 1993;343:145-57. Review. No abstract available.

PMID:
7514333
41.

A panel of monoclonal antibodies for the type I insulin-like growth factor receptor. Epitope mapping, effects on ligand binding, and biological activity.

Soos MA, Field CE, Lammers R, Ullrich A, Zhang B, Roth RA, Andersen AS, Kjeldsen T, Siddle K.

J Biol Chem. 1992 Jun 25;267(18):12955-63.

42.

Transdominant inhibition of tyrosine kinase activity in mutant insulin/insulin-like growth factor I hybrid receptors.

Treadway JL, Morrison BD, Soos MA, Siddle K, Olefsky J, Ullrich A, McClain DA, Pessin JE.

Proc Natl Acad Sci U S A. 1991 Jan 1;88(1):214-8.

43.
44.

Hybrid insulin receptors. Molecular mechanisms of negative-dominant mutations in receptor-mediated insulin resistance.

Whittaker J, Soos MA, Siddle K.

Diabetes Care. 1990 Jun;13(6):576-81. Review.

PMID:
2192845
46.

Monoclonal antibodies to the insulin receptor mimic metabolic effects of insulin but do not stimulate receptor autophosphorylation in transfected NIH 3T3 fibroblasts.

Soos MA, O'Brien RM, Brindle NP, Stigter JM, Okamoto AK, Whittaker J, Siddle K.

Proc Natl Acad Sci U S A. 1989 Jul;86(14):5217-21.

48.
49.

Monoclonal antibodies as probes of the structure and function of insulin receptors.

Siddle K, Soos MA, O'Brien RM, Ganderton RH, Taylor R.

Biochem Soc Trans. 1987 Feb;15(1):47-51. No abstract available.

PMID:
3549387
50.

Monoclonal antibodies reacting with multiple epitopes on the human insulin receptor.

Soos MA, Siddle K, Baron MD, Heward JM, Luzio JP, Bellatin J, Lennox ES.

Biochem J. 1986 Apr 1;235(1):199-208.

Supplemental Content

Support Center